DBV Technologies | DBVT - Selling And Administration Expenses


DBV Technologies reported $13.4M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
DBV Technologies USD 13.4M 8.14M Mar/2026
Galectin Therapeutics USD 1.48M 110K Jun/2024
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Insmed USD 247.47M 208K Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 206.7M 50.1M Jun/2026